Your browser doesn't support javascript.
loading
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka, Michael; Koenig, Lars M; Formisano, Simone; Boehmer, Daniel F R; Vick, Binje; Heuer, Eva-M; Meinl, Hanna; Kocheise, Lorenz; Zeitlhöfler, Marcus; Ahlfeld, Julia; Kobold, Sebastian; Endres, Stefan; Subklewe, Marion; Duewell, Peter; Schnurr, Max; Jeremias, Irmela; Lichtenegger, Felix S; Rothenfusser, Simon.
Afiliación
  • Ruzicka M; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Koenig LM; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Formisano S; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
  • Boehmer DFR; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Vick B; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Heuer EM; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
  • Meinl H; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Kocheise L; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Zeitlhöfler M; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Ahlfeld J; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Kobold S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Endres S; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
  • Subklewe M; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Duewell P; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
  • Schnurr M; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
  • Jeremias I; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Lichtenegger FS; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.
  • Rothenfusser S; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
Leukemia ; 34(4): 1017-1026, 2020 04.
Article en En | MEDLINE | ID: mdl-31740809
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Virales / ARN Bicatenario / Leucemia Mieloide Aguda / Anticuerpos Neutralizantes / Proteína 58 DEAD Box / Inmunoterapia Tipo de estudio: Prognostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Virales / ARN Bicatenario / Leucemia Mieloide Aguda / Anticuerpos Neutralizantes / Proteína 58 DEAD Box / Inmunoterapia Tipo de estudio: Prognostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article